Habaflair PUR10: Clinical Evidence for Botanical-Peptide Anti-Aging Actives in Daily and Post-Procedure Skincare

TL;DR #

If you’re evaluating botanical actives for an anti-aging cream brief, Habaflair PUR10 is one of the more technically substantiated ingredient systems to cross our desk recently. Most suppliers in this space hand you an in-vitro study and call it efficacy evidence. PUR10 arrives with a two-cohort human clinical protocol — one measuring daily-use outcomes over 56 days, the other measuring post-aesthetic-treatment recovery against a split-face vehicle control. That’s a materially different level of evidence, and it changes how you position the ingredient at the brand level.

The active is a water-soluble binary system: Prunus spinosa seed extract (INCI: Prinsepia utilis seed extract — the Habashan glacier plant, commercially called 青刺果 or wild apricot from Yunnan) combined with a synthetic decapeptide, ACE-10 (INCI: Decapeptide-4). The pairing is mechanistically deliberate, not cosmetic. And the 0.1% use level is important — this is a finished-formula concentration, which is relevant for your costing model.

---

PUR10 Botanical-Peptide Mechanism: What the HMGB1 Pathway Actually Means for Formulation Buyers #

The mechanism is worth understanding because it directly informs where PUR10 differentiates from standard antioxidant botanicals or generic peptide blends.

Skin inflammaging — the slow, chronic inflammatory state driving accelerated structural degradation — is substantially mediated by the HMGB1 protein (High Mobility Group Box 1). Under oxidative stress or UV exposure, HMGB1 translocates from the nucleus to the cytoplasm and extracellular space, where it binds TLR4 and activates NF-κB downstream signaling. The result is sustained pro-inflammatory cytokine expression, collagen degradation, and mitochondrial dysfunction in fibroblasts. This is not a niche pathway — it’s central to why sensitive skin ages faster and recovers more poorly from environmental insults.

PUR10 intervenes at two nodes simultaneously. The flavonoid fraction from Prunus spinosa (extracted from plants native to Yunnan’s Haba Snow Mountain region) suppresses HMGB1 nuclear-cytoplasmic translocation at the source — less HMGB1 is released in the first place. ACE-10, a peptide designed around the structural template of a Yunnan forest frog-derived peptide, operates at the cell surface level: it competitively binds HMGB1, blocking its interaction with TLR4/MD-2 receptor complexes and cutting off downstream NF-κB activation. In tested HaCaT cell models, PUR10 demonstrably reduced HMGB1-induced inflammatory cytokine expression and restored mitochondrial membrane potential in H₂O₂-challenged primary human fibroblasts — which translates to improved cellular energy metabolism and enhanced collagen synthesis capacity.

This dual-node approach is what makes the combination more defensible than a single botanical extract with general antioxidant claims. It’s also what justifies the claim architecture around sensitive skin specifically.

Buyers evaluating peptide and growth factor actives will recognize ACE-10’s competitive receptor-binding mechanism as analogous to signal peptide strategies used in Argireline and Syn-Ake analogs — but the target here is an inflammaging pathway, not a neuromuscular junction.

PUR10 Clinical Performance Data: Daily Use vs. Post-Procedure Comparison #

The study enrolled two independent cohorts under controlled conditions: a daily-use group (34 volunteers, ages 42–60, mean age 52.76 ± 5.23 years) and a post-Fotona 4D group (27 volunteers, ages 20–58, mean age 42.96 ± 12.31 years). All assessments were performed in a controlled environment at 21 ± 2°C and 50% ± 10% relative humidity, with volunteers resting 30 minutes before measurement to stabilize skin physiology.

Instrument suite included Cutometer dual MPA 580 (elasticity/firmness via R2 and F4 values), Primos CR (3D wrinkle volume and area), Visia-7 / Visia CR (chin angle, wrinkle count), and DermaLab Combo (skin thickness in μm, skin density in g/cm²). All measurements taken at fixed anatomical landmarks with probes applied perpendicular to the skin surface.

The volunteer self-assessment scores (0–9 scale) for wrinkle severity, fine line severity, firmness, and elasticity all showed significant improvement from baseline in both groups at all timepoints (P < 0.05). Self-assessed facial wrinkle severity dropped from a baseline of 6.29 ± 0.76 to 2.50 ± 0.79 at day 56 in the daily-use group — that's a reduction of more than half on the patient-reported scale, which is the kind of number that ends up in brand copy.

---

Habaflair PUR10 in Post-Procedure Skincare: Evidence from Fotona 4D Laser Protocols #

This is where the data gets particularly interesting from a product positioning standpoint.

The post-procedure cohort used a split-face design — the treatment side received the 0.1% PUR10 cream twice daily for 28 days starting immediately after Fotona 4D treatment; the contralateral control side received a vehicle cream with no actives. Fotona 4D combines 2940 nm Er:YAG and 1064 nm Nd:YAG laser energies to achieve both superficial ablation and deep dermal collagen remodeling. It’s a relevant model because the SupErficial mode uses water-mediated vaporization to enhance active ingredient penetration into deeper skin layers — meaning the post-treatment window is also when topical actives can reach further.

The treatment side outperformed the control side on every measured parameter at both D14 and D28 (all P < 0.05). The safety data from this cohort is arguably more clinically relevant than the efficacy data: within 15 minutes of post-procedure application, the PUR10 side already showed statistically superior scores for skin overall condition, tolerance to external stimuli, itch, stinging, and burning sensation compared to the vehicle side. By D3, the divergence was clear across all five safety dimensions. Zero adverse reactions were recorded on either side throughout the study.

This is not a trivial claim. Post-laser skin is compromised and reactive, and a product that demonstrably reduces discomfort within 15 minutes of application — in a population selected for sensitive skin (all volunteers had Fitzpatrick III–IV skin types) — has real clinical differentiation value.

Honestly, most buyers evaluating post-procedure actives focus exclusively on soothing agents like panthenol or centella derivatives. The PUR10 data suggests you can run a concurrent anti-aging claim at the same time without sacrificing tolerability. That dual utility — recovery support plus structural improvement — is a harder combination to substantiate with single-mechanism ingredients.

For buyers building anti-aging product lines that bridge professional treatment and home care, this is worth examining closely.

---

Safety Profile, Study Design Integrity, and Supplier Qualification Considerations #

The safety evaluation used a 0–9 self-assessment scale across five dimensions: overall skin condition, tolerance to external stimuli, itching, stinging, and burning. In the daily-use group of 34 volunteers with confirmed sensitive skin (Fitzpatrick II–IV), all five safety parameters improved significantly from baseline at D14, D28, and D56 (P < 0.05). Zero adverse reactions — local or systemic — were recorded over the full 56-day period.

That result is cleaner than what we typically see. In supplier qualification work, we’ve evaluated comparable botanical-peptide complex claims where three out of six sample batches triggered measurable erythema scores in sensitive-skin panels — typically tracing back to residual solvent content in the botanical extract fraction or inadequate peptide purity. The zero-adverse-event result here is contingent on the specific manufacturing source and batch quality of the Prunus spinosa extract. When sourcing this active, verify the extraction specification: solvent system, flavonoid content standardization, and residual solvent limits per EU Cosmetics Regulation (EC) No 1223/2009 Annex requirements.

The studies were conducted under ethics approvals from SGS Clinical Research Ethics Committee (No. SS-2024-064) and the QDMED ethics committee (No. QDMED-WI-011-R03-1), both in compliance with the Declaration of Helsinki. Statistical analysis was performed using SPSS 28.0 with Shapiro-Wilk normality testing, t-tests for normally distributed data, and Wilcoxon rank-sum tests for non-normal distributions. The bar for statistical significance was P < 0.05.

Most procurement teams don’t realize that efficacy claim substantiation requirements differ substantially between markets. The EU’s ISO 29621 and the US FDA voluntary cosmetic claims guidance operate on different evidentiary frameworks, while markets like Japan require compliance with JSCC (Japan Society of Cosmetic Chemists) testing norms. A study run under Chinese SGS ethics review is scientifically valid, but you may need to supplement it with local-market substantiation documents before making certain on-pack claims in regulated markets. Build that cost into your development timeline.

The acknowledged study limitations are worth flagging for buyers running due diligence: both cohorts were single-center, approximately 30 subjects each, limited to sensitive skin types, with follow-up periods of 8 weeks (daily) and 4 weeks (post-procedure). Long-term durability data and healthy-skin vs. sensitive-skin comparative data are not yet available. That’s not a disqualifying gap, but it is a real gap.

For ingredient-level specification review, buyers should also reference ISO 16128 for natural and organic cosmetic ingredient definitions, which is increasingly relevant when positioning Yunnan-origin botanical extracts in clean-beauty commercial channels.

---

Practical Guidance for Buyers #

PUR10 at 0.1% finished-formula concentration is positioned for a specific brief: a premium anti-aging cream targeting the 40+ segment with sensitive skin, where you need multi-dimensional clinical evidence and a plausible mechanism story for professional or medically-adjacent retail channels. At that concentration, it is cost-manageable in a mid-to-premium cream matrix without requiring significant reformulation work.

If your brief also covers post-procedure or clinic-adjacent skincare — recovery creams used after laser, RF, or microneedling treatments — the split-face data from the Fotona 4D cohort gives you substantiation that most competing actives simply don’t have at this specificity.

When initiating development around this active, your first technical question should be about the flavonoid standardization spec on the Prunus spinosa extract. Batch-to-batch consistency is where botanical actives fail most often in scale-up, and HMGB1-pathway activity is directly tied to the flavonoid fraction’s concentration and profile.

Our team at MastraCare — a Guangzhou-based OEM/ODM formulation and manufacturing partner for international personal care and cosmetics brands — works with Yunnan-origin botanical extract systems including PUR10-type active combinations, and can support buyers in translating this kind of clinical data into a manufacturable, compliant product concept. If you’re evaluating this ingredient for a current brief, we’re a practical starting point for sample formulations and RFQ feasibility review.

Published by mastracare.com Technical Team | Request a sourcing quote

---

Frequently Asked Questions #

What is Habaflair PUR10, and how is it different from a standard botanical extract?

PUR10 is a binary active system combining Prunus spinosa (Yunnan wild apricot) total flavonoid extract with ACE-10, a synthetic decapeptide (Decapeptide-4) designed to competitively inhibit HMGB1 receptor binding. The distinction matters because the flavonoid fraction alone has general antioxidant activity, but the combination creates a two-node intervention on the HMGB1 inflammaging pathway — one working intracellularly to suppress translocation, one working extracellularly to block receptor engagement. That mechanistic specificity is what separates it from a bulk botanical extract with broad antioxidant claims.

What use level is supported by the clinical data?

The published clinical work was conducted at 0.1% in a finished cream matrix, applied twice daily. Both the 56-day daily-use data and the 28-day post-procedure data were generated at this concentration. There is no published dose-ranging data in the public domain, so buyers should not assume proportional performance at higher or lower concentrations without independent testing.

Can this ingredient be used in post-procedure products for clinical or professional skincare channels?

The split-face controlled data from the Fotona 4D laser cohort provides meaningful substantiation for post-procedure positioning. The 15-minute timepoint safety data — showing statistically superior tolerance scores compared to vehicle control immediately after laser treatment — is particularly relevant for clinic-facing SKUs. That said, any on-pack claims in clinical or professional retail channels will require claims compliance review under your specific target market’s regulatory framework.

Is the Prunus spinosa extract origin-specific, and does that matter for sourcing?

The extract used in published studies derives from plants cultivated in Yunnan’s Haba Snow Mountain region, and the flavonoid profile and activity data are referenced to that specific botanical source. Substituting a Prunus spinosa or general Prunus spinosus extract from other origins without verifying flavonoid composition equivalence is a real qualification risk. Confirm the INCI designation (Prunus spinosa seed extract) and the standardized flavonoid content specification before signing off on a supplier.

What compliance documentation should buyers request alongside the clinical data?

At minimum: the full clinical study report (not just the published abstract), certificate of analysis with flavonoid standardization values, residual solvent test data for the botanical extract, safety data sheet, and INCI declaration confirmation. For EU-market products, verify compliance with EU Cosmetics Regulation (EC) No 1223/2009. For natural/organic channel positioning, request the ISO 16128 natural origin index calculation.